12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Taliglucerase alfa regulatory update

FDA issued a complete response letter for an NDA from Protalix for Gaucher's disease candidate taliglucerase alfa. According to the company, the agency requested CMC information about testing specifications and assay...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >